Uttarakhand takes steps for environmentally responsible disposal of medicines
Chief Minister Pushkar Singh Dhami has started work towards implementing the guidelines issued by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare in the state.
This decision is not just an administrative process, but a transformative initiative towards making Uttarakhand a model state of "
green health system
" across the country, a release said.
Health Secretary and Commissioner of the FDA, Dr. R. Rajesh Kumar, said that till now, there has been a lack of a clear and consistent system for the disposal of expired and unused medicines.
"This challenge becomes more serious in an environmentally sensitive state like Uttarakhand. Now we are moving towards controlling it under a well-planned system," Kumar said.
He informed that in these guidelines, the process has been decided keeping in mind every stage of the life cycle of medicines from production to consumption and then proper disposal.
Kumar further said that under the "Healthy Citizen, Clean Uttarakhand" mission announced by the Chief Minister, this initiative will take the state towards a green and sustainable healthcare model.
With this decision, the possibility of establishing the state as a leading state in the field of environmental responsibility and health security at the national and international level has also become stronger.
Only the active participation of all the parties involved in this entire process, policy makers, business organizations and common citizens can make this mission successful. Uttarakhand is moving towards becoming an example in this direction.
Dr. R. Rajesh Kumar informed that as per the plan of the Health Department, "
Drug Take-Back Sites
" will be set up in a phased manner in urban, semi-urban and hilly areas of Uttarakhand.
Here common citizens will be able to deposit unused, expired or spoiled medicines lying in their homes. Medicines from these centers will be collected scientifically and disposed of in specially approved processing units.
Dr. R. Rajesh Kumar said that the CDSCO guideline presents a scientific framework for safe disposal of medicines. It has a provision to divide medicines into categories like expired, unused, recalled and spoiled in cold chain. Techniques like incineration and encapsulation have been suggested for disposal.
Arrangements like color-coded biomedical waste bags, tracking and log book system make it more effective. This guideline has been prepared in accordance with WHO standards and Biomedical Waste Management Rules 2016, so that the side effects of medicines on human health and environment can be reduced.
Additional Commissioner FDA and Drug Controller Tajbar Singh Jaggi said that the system that was in place till now regarding the disposal of medicines in the state was scattered and unorganized.
"Now we will control it through a 'third party monitoring system' and local drug enforcement units. Accountability will be fixed for all the manufacturing companies, wholesalers and retailers, hospitals and consumers. We will also run extensive public awareness campaigns in this direction so that common citizens also become partners in this system," Jaggi said.
He further added that this step is necessary because uncontrolled disposal of medicines can pose a serious threat not only to the environment but also to public health. Such disposal can lead to mixing of toxic chemicals in rivers, lakes and underground water sources, which harms natural resources. At the same time, if the medicines come in contact with animals or children, a serious health crisis can arise.
Apart from this, global problems like antimicrobial resistance (AMR) can also increase due to wrong and excessive use of medicines. The Uttarakhand government has made solid preparations to deal with these challenges.
The Additional Commissioner and Drug Controller said that the State Drug Control Department would be made the monitoring agency, the Druggists and Chemists Association would be linked to the take-back system, task forces would be formed in the districts and arrangements would be made for monitoring and audit of data through the e-drug log system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
42 minutes ago
- Time of India
Mumbai police order CCTV cameras at medical stores in a month to curb illegal drug sales
Mumbai: To check illegal sale of scheduled drugs, the Mumbai police has asked all pharmacy stores to install CCTV cameras in their premises within a month. Owners of medical stores and chemist shops are unhappy with the move as they believe such measures will not help. Scheduled drugs refer to medications regulated under the Drugs and Cosmetics Rules, 1945, on the basis of how they are manufactured, stored, distributed, and prescribed. For instance, Schedule H includes prescription drugs that cannot be sold without a doctor's prescription and Schedule X refers to prescription drugs that are highly addictive You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai The directive, issued under Section 152 of the Indian Civil Security Code, 2023, by deputy commissioner of police (anti-narcotics cell) Navnath Dhawale, is based on intelligence inputs. The Narcotics Control Bureau (NCB) and the Commission for Protection of Child Rights, New Delhi, too, had recently raised concerns about the sale of scheduled drugs and inhalants without valid prescriptions. The Anti-Narcotics Cell and Food and Drug Administration (FDA) found several medical stores in Mumbai sold habit-forming drugs without maintaining proper records. According to the order, every medical shop in Mumbai and its suburban districts will have to install CCTV cameras at all entrances, exits, and sale counters in such a way that the faces of customers and transactions are recorded. The cameras must have a minimum resolution of 2 megapixels, and footage must be stored for at least one month. Officials from the District Drug Control Authority and Child Welfare Police Officers can inspect CCTV footage. Medical shop owners have been given a 30-day period to comply with the order. Senior officials said the initiative is part of a larger crackdown on the misuse of prescription drugs, often diverted into the narcotics trade. Abay Pandey, president of the All Food and License Holders Foundation, told TOI: "Firstly, the police have no powers to check medical stores if there are not accompanied by FDA officials. Secondly, these CCTV cameras won't serve any purpose as the prescriptions and medicine strips are written in small fonts. How is the camera going to help them?" Prasad Danave, president of Retail and Dispensing Chemist Association Mumbai, said, "How is the camera going to keep a tab on the medicines sold? What about the online sites that sell abortion pills to a 14-year-old girl? Is there any check on them?"
Mint
an hour ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
Time of India
9 hours ago
- Time of India
How to get a job at the FDA? Here's everything young professionals should know
The US Food and Drug Administration (FDA) is one of the most influential public health agencies in the world. From regulating the food we eat and the medicines we take, to overseeing cutting-edge medical devices and vaccines, the FDA plays a vital role in shaping the nation's health landscape. Tired of too many ads? go ad free now For students and young professionals who want to make a meaningful impact on public health, a career at the FDA offers both purpose and prestige. But how exactly does one get started? What the FDA actually does While many think of the FDA purely as a science agency, its responsibilities stretch far beyond the lab. The agency hires professionals from a wide range of backgrounds—scientists, doctors, engineers, data analysts, public health experts, lawyers, policy makers, and even communicators and IT specialists. For instance, if you're majoring in biology or chemistry, you might fit into roles dealing with food safety or pharmaceutical review. If you're a public health student, epidemiology and regulatory policy might interest you. Law and political science graduates can pursue careers in compliance or policy analysis, while engineers may work on assessing medical device safety. In short, there's no single path in—there are many. Building the right educational foundation Most positions at the FDA require at least a bachelor's degree, and more technical or research-heavy roles often prefer a master's, PhD, PharmD, JD, or MD. Students hoping to enter scientific or regulatory careers should pursue degrees in fields like biology, microbiology, pharmacology, toxicology, biochemistry, or biomedical engineering. Those interested in policy, law, or communication can major in public health, public administration, political science, or law. Tired of too many ads? go ad free now Academic excellence is important, but what also stands out is coursework or experience in areas like data analysis, clinical trials, research methods, bioethics, or FDA regulatory systems. Taking relevant electives or doing a thesis related to health regulation or safety can strengthen your application. Internships and fellowships: The smartest entry points If you're still in school, or recently graduated, your best bet is to gain entry through an internship or fellowship. The FDA offers multiple programs designed specifically for early-career professionals. One of the most accessible is the Pathways Program, which includes internships for current students and special hiring opportunities for recent graduates. These positions are paid and often lead to full-time roles within the agency. For those with advanced degrees, the FDA Commissioner's Fellowship Program is highly prestigious. This two-year, full-time program gives fellows the chance to work on real-world regulatory issues and collaborate with leading FDA scientists and policy makers. There's also the ORISE Fellowship Program, which partners with the FDA to offer short- and long-term research positions. These fellowships are ideal for students in STEM fields who want to gain hands-on experience in public health and regulatory science. Each summer, the FDA also hosts students for short-term research internships in labs and policy offices. These summer opportunities are competitive, but they offer valuable exposure to the agency's mission and operations. Navigating the federal hiring system All permanent jobs and many internships at the FDA are posted on the official job portal for the USgovernment. Applying through this site can feel intimidating at first, but it's manageable once you understand the format. First, you'll need to create a USAJobs account and upload a federal-style resume—which is usually much longer and more detailed than private-sector resumes. These resumes should include your full education history, detailed descriptions of work and volunteer experience, skills, certifications, and any honors or awards. Job announcements on the site are detailed and may include questionnaires, writing samples, or transcripts. Be sure to read each posting thoroughly, tailor your application to the specific role, and submit all required documents before the deadline. The citizenship question and international applicants It's important to note that most FDA jobs require US citizenship, especially for permanent roles. However, students or researchers who are not citizens may still be eligible for certain internships or fellowships, especially those run through academic institutions or programs like ORISE. International students interested in working with the FDA should consider partnerships through US universities or look for collaborative opportunities with other international health organizations. The bottom line Joining the FDA is not just about credentials—it's about passion for public service, dedication to science and health, and a willingness to learn. Start early by exploring internship opportunities, talking to mentors in your field, and following the agency's work in current affairs. Working at the FDA means having a front-row seat to decisions that affect millions. For students and young professionals, it's a place where your knowledge can meet real-world impact. TOI Education is on WhatsApp now. Follow us .
